ArticleThe Kaohsiung journal of medical sciences2026
Hypoxia-Induced Histone Lactylation Promotes Ferroptosis in Cardiomyocytes via the Wnt/β-Catenin Pathway.
Article in The Kaohsiung journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Histone Modifications in Cardiovascular Disease: Mechanisms and Therapeutic Opportunities.MedComm · 2026Review
- Lactylation-regulated ferroptosis: mechanisms, disease associations, and therapeutic strategies.Archives of pharmacal research · 2026Review
- Hypoxia-Induced Histone Lactylation Promotes Ferroptosis in Cardiomyocytes via the Wnt/β-Catenin Pathway.The Kaohsiung journal of medical sciences · 2026Article
- Histone lactylation-mediated glycolysis-ferroptosis axis in neurological diseases.Frontiers in molecular neuroscience · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
This study investigated the effects of histone lactylation on ferroptosis in hypoxia-induced cardiomyocytes. A hypoxia model was established in AC16 cells treated with 2-Deoxy-D-glucose (2-DG, a glucose analogue), ferrostatin-1 (Fer-1, a selective ferroptosis inhibitor), lactate (LA), sh-β-catenin (shRNA of β-catenin), or SKL2001 (an agonist of the Wnt/β-catenin pathway) for subsequent experiments. Hypoxia increased glycolysis ability, HK2, PDK1, and LDHA mRNA expression, HK and LDH activities, and LA levels in AC16 cells, decreased SLC7A11 and GPX4 protein levels and GSH levels, and elevated iron ion, MDA, and ROS levels, Wnt3 and nuclear β-catenin protein levels, β-catenin nucleus entry, the overall level of lactylation, the lactylation of β-catenin, and β-catenin protein stability. 2-DG or Fer-1 treatment reduced iron ion, MDA, and ROS levels but increased SLC7A11 and GPX4 protein levels and GSH levels in hypoxia-treated cells. 2-DG treatment decreased Wnt3 and nuclear β-catenin protein levels, β-catenin nucleus entry, the overall level of lactylation, the lactylation of β-catenin, and β-catenin protein stability, whereas LA treatment produced the opposite effects. Wnt/β-catenin pathway repression attenuated hypoxia-induced ferroptosis in cardiomyocytes. Collectively, hypoxia enhances histone lactylation, activates the Wnt/β-catenin pathway, and increases β-catenin stability, thereby promoting ferroptosis in cardiomyocytes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.